Inosine pranobex

PreclinicalSmall molecule

NNewport Pharmaceuticals International

Inosine pranobex is one of 31 small molecule programs targeting Double-blind. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindCompleted

Lymph Node DiseaseCompleted

AIDSCompleted

LymphadenopathyCompleted

Double-BlindPreclinical

Completed

Lymph Node DiseasePreclinical

Completed

AIDSPreclinical

Completed

LymphadenopathyPreclinical

Completed

Competition

Competitive Landscape

25 competitors in AIDS

#DrugCompanyPhaseTrials

Aralen

Tivicay

Vemlidy

Emtriva

Tybost

Norvir

Thalomid

Viramune

Prezista

Fuzeon

CConrado Roberto Hoffmann Filho

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Inosine pranobex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inosine pranobex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inosine pranobex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newport Pharmaceuticals International company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNewport Pharmaceuticals International

Inosine pranobex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Double-blind2 trials

Lymph Node Disease2 trials

Lymphadenopathy1 trial

Trial1 trial

AIDS1 trial

References

Drug Info

Quick Facts

Related News